Last reviewed · How we verify

TNM002 — Competitive Intelligence Brief

TNM002 (TNM002) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1 inhibitor. Area: Oncology.

phase 3 PD-1 inhibitor PD-1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

TNM002 (TNM002) — Zhuhai Trinomab Pharmaceutical Co., Ltd.. TNM002 is a monoclonal antibody targeting PD-1.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
TNM002 TARGET TNM002 Zhuhai Trinomab Pharmaceutical Co., Ltd. phase 3 PD-1 inhibitor PD-1
Tevimbra TISLELIZUMAB Beigene marketed Programmed Death Receptor-1 Blocking Antibody [EPC] Pd-1 2025-01-01
Penpulimab kcqx PENPULIMAB Akeso Biopharma marketed Pd-1 2025-01-01
Unloxcyt COSIBELIMAB Checkpoint Therapeutics Inc marketed Programmed Death Ligand-1 Blocker [EPC] Pd-1 2024-01-01
Loqtorzi TORIPALIMAB Coherus Biosciences Inc marketed Programmed Death Receptor-1 Blocking Antibody [EPC] Pd-1 2024-01-01
Jemperli DOSTARLIMAB GSK marketed Programmed Death Receptor-1 Blocking Antibody [EPC] PD-1 2021-01-01
Libtayo CEMIPLIMAB Regeneron Pharmaceuticals marketed PD-1 2018-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1 inhibitor class)

  1. Sun Yat-sen University · 11 drugs in this class
  2. Bristol-Myers Squibb · 9 drugs in this class
  3. Addpharma Inc. · 7 drugs in this class
  4. Merck Sharp & Dohme LLC · 5 drugs in this class
  5. Shanghai Henlius Biotech · 5 drugs in this class
  6. Innovent Biologics (Suzhou) Co. Ltd. · 5 drugs in this class
  7. Pfizer · 4 drugs in this class
  8. Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 4 drugs in this class
  9. Amgen · 3 drugs in this class
  10. Daewoong Pharmaceutical Co. LTD. · 3 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TNM002 — Competitive Intelligence Brief. https://druglandscape.com/ci/tnm002. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: